Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

doi:10.1016/S2215-0366(16)30065-7

Paper

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

Published Jul 1, 2016 · R. Carhart-Harris, M. Bolstridge, J. Rucker

The lancet. Psychiatry

Q1 SJR score

983

Citations

66

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Rigorous Journal

Highly Cited

Study Snapshot

Psilocybin shows preliminary safety and efficacy in treating treatment-resistant depression, with marked improvements in depressive symptoms, anxiety, and anhedonia.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

References

Citations